Skip to content

Study · Randomized controlled trial · 2010

2 results

[Effectiveness of cortexin in the complex treatment of patients with chronic alcohol encephalopathy and polyneuropathy].

Solov'ev AG, Elistratova TV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2010

PMID20517210 (opens in a new tab)PepBankPUB-20517210
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with alcohol disorders or polyneuropathy, cortexin had a positive combined clinical and electrophysiological effect.

    In plain wordsIn patients with alcohol disorders or polyneuropathy, cortexin had a positive combined clinical and electrophysiological effect.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseCombined clinical and electrophysiological response
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 mg/d · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Cortexin had the positive effect on clinical symptoms, EEG and ENMG.
    4 context sentences
    Summary · context
    Investigation of therapeutic effectiveness of cortexin in chronic alcohol encephalopathy and chronic alcohol polyneuropathy was conducted in an open randomized study.
    Summary · context
    Cortexin was prescribed in dose 10 mg/d intramuscular during 10 days, along with standard therapy.
    Summary · context
    The group of patients consisted of 15 people with alcohol disorders, 15 people with diabetic polyneuropathy and 15 people with professional polyneuropathy.
    Summary · context
    The control group included 15 patients with alcohol disorders who did not receive cortexin.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with alcohol disorders or polyneuropathy, cortexin was well tolerated without observed side effects.

    In plain wordsIn patients with alcohol disorders or polyneuropathy, cortexin was well tolerated without observed side effects.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableSide effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg/d · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    The drug was well-tolerated, no side-effects were observed.
    4 context sentences
    Summary · context
    Investigation of therapeutic effectiveness of cortexin in chronic alcohol encephalopathy and chronic alcohol polyneuropathy was conducted in an open randomized study.
    Summary · context
    Cortexin was prescribed in dose 10 mg/d intramuscular during 10 days, along with standard therapy.
    Summary · context
    The group of patients consisted of 15 people with alcohol disorders, 15 people with diabetic polyneuropathy and 15 people with professional polyneuropathy.
    Summary · context
    The control group included 15 patients with alcohol disorders who did not receive cortexin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.